President Donald Trump announced Tuesday that U.S. Food and Drug Administration Commissioner Marty Makary has resigned [1].
The departure of the FDA head is significant because the agency regulates roughly one-fifth of all consumer products in the United States [2]. This leadership vacuum comes at a time of high political tension surrounding public health policy and drug regulation.
"Marty Makary is out," Trump said in a statement [3].
The resignation follows weeks of mounting pressure from Republican lawmakers and anti-abortion groups [4]. Reports indicate that Makary also faced internal clashes with White House health advisers over several controversial policy decisions [4].
Specific friction centered on the fallout from the mifepristone abortion-pill controversy [5]. While some reports state Makary resigned on May 12, 2026 [1], other accounts suggest he announced his intention to step down with an effective date yet to be confirmed [6].
Makary's tenure was marked by a struggle to balance the administration's political goals with the agency's regulatory framework. The pressure from powerful Republicans and advocacy groups eventually made his position untenable, leading to the announcement from the White House [4].
“"Marty Makary is out," President Donald Trump said in a statement.”
The resignation of the FDA Commissioner reflects the intense political volatility surrounding reproductive health and drug approvals. By removing Makary amid pressure from anti-abortion groups and GOP lawmakers, the administration signals a shift toward a leadership style more closely aligned with its political base, potentially altering how the agency handles controversial medication and regulatory oversight.
